These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 37187125)

  • 21. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
    Balla A; Bhak J; Biró O
    Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of HTLV-1 proviral DNA in cell-free DNA: Potential for non-invasive monitoring of Adult T cell leukaemia/lymphoma using liquid biopsy?
    Joris T; Haddow J; Taylor GP; Cook LBM; Rowan AG
    Front Immunol; 2023; 14():1150285. PubMed ID: 37114063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Size distribution of cell-free DNA in oncology.
    Udomruk S; Orrapin S; Pruksakorn D; Chaiyawat P
    Crit Rev Oncol Hematol; 2021 Oct; 166():103455. PubMed ID: 34464717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology.
    Ray SK; Mukherjee S
    Curr Pharm Biotechnol; 2022; 23(1):112-122. PubMed ID: 33308128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?
    Yuan Z; Wang X; Geng X; Li Y; Mu J; Tan F; Xue Q; Gao S; He J
    Cancer Commun (Lond); 2021 Jan; 41(1):3-15. PubMed ID: 33264481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
    Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
    PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.
    Seyhan AA
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards effectiveness of cell free DNA based liquid biopsy in head and neck squamous cell carcinoma.
    Kowal-Wisniewska E; Jaskiewicz K; Bartochowska A; Kiwerska K; Ustaszewski A; Gorecki T; Giefing M; Paluszczak J; Wierzbicka M; Jarmuz-Szymczak M
    Sci Rep; 2024 Jan; 14(1):2251. PubMed ID: 38278927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinatory Analysis of Cell-free and Circulating Tumor Cell DNAs Provides More Variants for Cancer Treatment.
    Lee SY; Chae DK; An J; Yoo S; Jung S; Chae CH; Bhak J; Kim BC; Cho DH
    Anticancer Res; 2019 Dec; 39(12):6595-6602. PubMed ID: 31810925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer.
    Gianni C; Palleschi M; Merloni F; Di Menna G; Sirico M; Sarti S; Virga A; Ulivi P; Cecconetto L; Mariotti M; De Giorgi U
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
    Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
    Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy.
    Gai W; Sun K
    Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.
    Gao Y; Zhou N; Liu J
    Cancer Control; 2024; 31():10732748241255548. PubMed ID: 38764160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid biopsy in CNS tumors: Current status & future perspectives.
    Husain N; Husain A; Mishra S; Srivastava P
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities.
    Liebs S; Eder T; Klauschen F; Schütte M; Yaspo ML; Keilholz U; Tinhofer I; Kidess-Sigal E; Braunholz D
    Oncogene; 2021 Aug; 40(33):5204-5212. PubMed ID: 34230613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients.
    Igari F; Tanaka H; Giuliano AE
    Crit Rev Oncol Hematol; 2022 Jul; 175():103725. PubMed ID: 35618229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
    Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
    Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leveraging circulating microbial DNA for early cancer detection.
    Kataria R; Shoaie S; Grigoriadis A; Wan JCM
    Trends Cancer; 2023 Nov; 9(11):879-882. PubMed ID: 37659908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.